PD-1抑制剂治疗肝炎相关原发性肝癌的病毒再激活研究进展  

Research progress on viral reactivation of PD-1 inhibitors in the treatment of hepatitis-related liver cancer

作　　者：刘月圆(综述) 刘建婷 张荣生(审校) LIU Yueyuan;LIU Jianting;ZHANG Rongsheng(Department of Oncology,The First Affiliated Hospital of Dali University,Dali,Yunnan 671000,China)

机构地区：[1]大理大学第一附属医院肿瘤科,云南大理671000

出　　处：《现代医药卫生》2024年第20期3558-3562,3567,共6页Journal of Modern Medicine & Health

摘　　要：原发性肝细胞癌(HCC)是我国最常见的恶性肿瘤之一,慢性乙型病毒性肝炎、慢性丙型病毒性肝炎是HCC发生的主要危险因素,因慢性感染促进程序性细胞死亡蛋白1(PD-1)/程序性死亡配体1(PD-L1)等免疫共抑制分子的释放,导致免疫耐受及肿瘤的发生。近年来,以免疫检查点抑制剂(ICIs)为主的综合治疗已广泛运用于晚期肿瘤的治疗,然而,其导致的乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)再激活相关研究报道较少,该文就PD-1/PD-L1抑制剂治疗肝炎相关原发性肝癌的病毒再激活进行综述。Primary hepatocellular carcinoma(HCC)is one of the most common malignant tumors in China.Chronic hepatitis B and chronic hepatitis C are the main risk factors for HCC.Chronic infection promotes the release of immune co-inhibitory molecules such as programmed cell death protein 1(PD-1)/programmed death ligand 1(PD-L1),which leads to immune tolerance and tumorigenesis.In recent years,comprehensive treatment based on immune checkpoint inhibitors(ICIs)has been widely used in the treatment of advanced tumors.However,there are few reports on the reactivation of hepatitis B virus(HBV)and hepatitis C virus(HCV)caused by ICIs.This article reviews the viral reactivation of PD-1/PD-L1 inhibitors in the treatment of hepatitis-related primary liver cancer.

关 键 词：PD-1抑制剂 免疫治疗 原发性肝细胞癌 肝炎病毒 病毒再激活 综述 

分 类 号：R735.7[医药卫生—肿瘤]